What does a non-response to induction chemotherapy imply in high-risk medulloblastomas?

Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol (Berl) 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1

Chang CH, Housepian EM, Herbert C (1969) An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93(6):1351–1359. https://doi.org/10.1148/93.6.1351

Dufour C, Foulon S, Geoffray A et al (2020) Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase 2 trial PNET HR+5. Neuro-Oncol. https://doi.org/10.1093/neuonc/noaa301

Taylor RE, Bailey CC, Robinson KJ et al (2005) Outcome for patients with metastatic (M2–3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer Oxf Engl. 41(5):727–734. https://doi.org/10.1016/j.ejca.2004.12.017

Gajjar A, Chintagumpala M, Ashley D et al (2006) Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7(10):813–820. https://doi.org/10.1016/S1470-2045(06)70867-1

Jakacki RI, Burger PC, Zhou T et al (2012) Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children’s Oncology Group Phase I/II study. J Clin Oncol Off J Am Soc Clin Oncol 30(21):2648–2653. https://doi.org/10.1200/JCO.2011.40.2792

Gandola L, Massimino M, Cefalo G et al (2009) Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol Off J Am Soc Clin Oncol 27(4):566–571. https://doi.org/10.1200/JCO.2008.18.4176

Le Teuff G, Castaneda-Heredia A, Dufour C et al (2020) Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study. Pediatr Blood Cancer 67(1):e28032. https://doi.org/10.1002/pbc.28032

Grill J, Geoerger B, Gesner L et al (2013) Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. Neuro-Oncol 15(9):1236–1243. https://doi.org/10.1093/neuonc/not097

Northcott PA, Shih DJH, Remke M et al (2012) Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol (Berl) 123(4):615–626. https://doi.org/10.1007/s00401-011-0899-7

Schwalbe EC, Williamson D, Lindsey JC et al (2013) DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol (Berl) 125(3):359–371. https://doi.org/10.1007/s00401-012-1077-2

Chukwueke UN, Wen PY (2019) Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol. https://doi.org/10.2217/cns-2018-0007

Chamberlain M, Junck L, Brandsma D et al (2017) Leptomeningeal metastases: a RANO proposal for response criteria. Neuro-Oncol 19(4):484–492. https://doi.org/10.1093/neuonc/now183

Dufour C, Beaugrand A, Pizer B et al (2012) Metastatic Medulloblastoma in Childhood: Chang’s Classification Revisited. Int J Surg Oncol 2012:245385. https://doi.org/10.1155/2012/245385

Choi LMR, Rood B, Kamani N et al (2008) Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors. Pediatr Blood Cancer 50(5):970–975. https://doi.org/10.1002/pbc.21381

Verlooy J, Mosseri V, Bracard S et al (2006) Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study. Eur J Cancer Oxf Engl 42(17):3004–3014. https://doi.org/10.1016/j.ejca.2006.02.026

Kortmann RD, Kühl J, Timmermann B et al (2000) Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT ’91. Int J Radiat Oncol Biol Phys 46(2):269–279. https://doi.org/10.1016/s0360-3016(99)00369-7

Sung KW, Yoo KH, Cho EJ et al (2007) High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr Blood Cancer 48(4):408–415. https://doi.org/10.1002/pbc.21064

Dufour C, Kieffer V, Varlet P et al (2014) Tandem high-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk medulloblastoma or supratentorial primitive neuro-ectodermic tumors. Pediatr Blood Cancer 61(8):1398–1402. https://doi.org/10.1002/pbc.25009

von Bueren AO, Kortmann R-D, von Hoff K et al (2016) Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters. J Clin Oncol Off J Am Soc Clin Oncol 34(34):4151–4160. https://doi.org/10.1200/JCO.2016.67.2428

Gentet JC, Doz F, Bouffet E et al (1994) Carboplatin and VP 16 in medulloblastoma: A phase II study of the French Society of Pediatric Oncology (sfop). Med Pediatr Oncol 23(5):422–427. https://doi.org/10.1002/mpo.2950230506

Tarbell NJ, Friedman H, Polkinghorn WR et al (2013) High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol Off J Am Soc Clin Oncol 31(23):2936–2941. https://doi.org/10.1200/JCO.2012.43.9984

Kool M, Korshunov A, Remke M et al (2012) Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol (Berl) 123(4):473–484. https://doi.org/10.1007/s00401-012-0958-8

Zeltzer PM, Boyett JM, Finlay JL et al (1999) Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol Off J Am Soc Clin Oncol 17(3):832–845. https://doi.org/10.1200/JCO.1999.17.3.832

Osorio DS, Dunkel IJ, Cervone KA et al (2018) Tandem thiotepa with autologous hematopoietic cell rescue in patients with recurrent, refractory, or poor prognosis solid tumor malignancies. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.26776

Pérez-Martínez A, Lassaletta A, González-Vicent M, Sevilla J, Díaz MA, Madero L (2005) High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. J Neurooncol 71(1):33–38. https://doi.org/10.1007/s11060-004-4527-4